Dear Colleague,
Despite the hundreds of kinase inhibitors currently in discovery and
pre-clinical phases, the number of kinase inhibitors which have been approved
and are on the market remains low by comparison. This discrepancy reflects the
challenges which accompany the development of ATP-competitive kinase inhibitors,
including low specificity and off-target binding. There is also the problem of
gatekeeper-associated drug resistance. To remain competitive in the kinase
field, stay abreast with recent development trends and
technological advancements aimed at circumventing these issues. We will also
provide you with a broad overview of the role kinases play in various types of
cancer and inflammatory diseases as well as introduce you to several novel kinases and inhibitor
candidates.
GTCbio is proud to present our 8th Protein Kinases in Drug Discovery
Conference! This meeting will be held July 8-9, 2013 at the
Westin Copley Place Boston Hotel in historical Boston, Massachusetts, one
of the most concentrated academic and industrial areas in the United States. We
will bring together industry leaders from major pharmaceutical companies,
biotech companies as well as top researchers from academia and government to
provide you with a better understanding of
the
structural basis of kinase regulation, complex activities of kinase networks in
the cells and emerging solutions to the current challenges associated with
kinase drug discovery and development. The meeting will offer you an intimate
forum to engage in discourse with other distinguished researchers involved in
the most cutting-edge kinase work!
Learn The Latest Trends in Kinase Drug Discovery:
- How cell
based screening can be used for the identification of new anti-cancer kinase
inhibitor candidates, inhibitor target ID and analysis of off-target effects
- Use of
physiologically relevant assays, structure-based drug design tools &
cheminformatics for more efficient kinase inhibitor discovery
-
Strategies to develop selective inhibitors by targeting inactive & active (DFG-out/in)
conformations of different classes of kinases
- Overview
of the preclinical development of kinase inhibitors for cancer &
inflammatory diseases
- Discovery
of new kinase signaling networks controlling cancer cell survival and
proliferation
-
Development of new strategies for overcoming cancer cell resistance to the
current tyrosine kinase inhibitors
Sessions for 2013 Agenda:
I.
Overcoming Challenges in Kinase Drug
Development
II. Trends in Drug Design & Screening Strategies
III. Mechanisms of Kinase Regulation
IV. Oncology Kinases & Inhibitor Candidates
V. Emerging Kinases & Inhibitor Candidates
Call for Papers (Poster Presentation)!
To be
considered for a short oral presentation, please submit an abstract
here
by June 9, 2013. Selected presentations will be based on quality of
abstract and availability. Presentation slots fill up fast so please submit your
abstract ASAP.
Sponsorship and exhibiting opportunities are available in a range of levels,
which can be tailored to fit your needs. Please contact 626-256-6405 x102 or spex@gtcbio.com for
more information.
Best
regards,
Organizing
Committee
|
|
PLATINUM
SPONSOR |
|
 |
|
| GOLD
SPONSORS |
|
 |
|
 |
|
|
|
